Vetirus Acquires Enso Discoveries to Expand Regenerative Med

Naples, Florida and London, UK® – February 10, 2025 – At  the 10th annual Animal Health, Nutrition and Technology Innovation Europe, Vetirus Pharmaceuticals announced its acquisition of Enso Discoveries, LLC, a Manhattan, Kansas-based biotech company specializing in regenerative medicine. This strategic acquisition enhances Vetirus’ capabilities in delivering innovative and cost-effective solutions to improve the lives of animals and humans worldwide.

Enso Discoveries is renowned for its development of cutting-edge products such as Rebound PRP™ and Rebound PRF®, which are widely used in veterinary and human health markets. These patented regenerative medicine kits provide accessible and validated therapies that promote optimal healing. Additionally, Enso Discoveries operates a state-of-the-art histopathology laboratory offering rapid, high quality diagnostic services for veterinarians.

Robert Jordan, CEO of Vetirus Pharmaceuticals, stated: “The acquisition of Enso Discoveries is an evolutionary step for Vetirus. Their expertise in regenerative medicine and their commitment to innovation align perfectly with our mission to redefine healthcare solutions globally.”

About Vetirus Pharmaceuticals

Vetirus Pharmaceuticals is a multinational company headquartered in Naples, Florida and London, UK. It focuses on biologic therapies that improve patient outcomes across human and veterinary markets.

About Enso Discoveries

Founded in 2014, Enso Discoveries specializes in regenerative medicine innovations for veterinary applications. The company is dedicated to delivering scientifically validated, cost-effective solutions that empower veterinarians and physicians globally.

Terms of the Deal

The financial terms of the acquisition remain confidential. However, both companies have confirmed that transaction includes the full transfer of Enso Disoveries’ intellectual property portfolio, including patents for its flagship products Rebound PRP™ and Rebound PRF®.

The Deal has been structured to allow for a seamless operational transition while leveraging Vetirus Pharmaceuticals’ global infrastructure to scale Enso’s innovative solutions. 

Strategic Benefits

This acquisition underscores Vetirus’ commitment to advancing regenerative medicine while expanding its global footprint. By integrating Enso Discoveries and expertise into its portfolio, Vetirus aims to accelerate research and development efforts while enhancing its ability to deliver groundbreaking therapies across veterinary and human health sectors.

Integration Plan

Vetirus Pharmaceuticals is working closely with Enso Discoveries’ leadership team to ensure a smooth integration process. The combined entity will focus on scaling production capabilities, expanding market access for existing products, and exploring new applications for regenerative medicine technologies. Both companies are committed to maintaining uninterrupted service for current customers during this transition.

For media inquiries or further information about this announcement:

Contact: Bailey Anderson

Email: contact@vetirus.com

Phone: (239) 298-1183